Parexel
Parexel International Corporation, commonly known as Parexel, is a leading global biopharmaceutical services provider headquartered in the United States. Founded in 1983, the company has established a strong presence in key operational regions, including Europe and Asia, delivering innovative solutions across the clinical research and regulatory consulting sectors. Specialising in drug development and regulatory affairs, Parexel offers a comprehensive suite of services that includes clinical trial management, biostatistics, and market access strategies. What sets Parexel apart is its commitment to advancing the development of new therapies while ensuring compliance with regulatory standards. With a robust market position, Parexel has achieved numerous milestones, including recognition for its excellence in clinical research. The company continues to play a pivotal role in the biopharmaceutical industry, helping clients navigate the complexities of bringing new drugs to market efficiently and effectively.
DitchCarbon Score
How does Parexel's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Parexel's score of 68 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Parexel's reported carbon emissions
In 2024, Parexel International Corporation reported total carbon emissions of approximately 323,408,000 kg CO2e. This figure includes 2,705,000 kg CO2e from Scope 1 emissions, 5,930,000 kg CO2e from Scope 2 emissions (location-based), and a significant 314,773,000 kg CO2e from Scope 3 emissions. The total emissions for 2023 were about 298,365,000 kg CO2e, indicating an increase in emissions year-on-year. Parexel has set ambitious climate commitments, aiming to reduce its absolute Scope 1 GHG emissions by 42% by 2030, using 2022 as the base year. Additionally, the company targets a 25% reduction in absolute Scope 3 GHG emissions by the same year. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to sustainable practices, including sourcing 100% renewable electricity through 2030. The company’s emissions data is not cascaded from any parent organisation, indicating that these figures are independently reported by Parexel. The focus on significant reductions in both Scope 1 and Scope 3 emissions highlights Parexel's proactive approach to addressing its carbon footprint within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 15,510,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 11,632,000 | 00,000,000 | 0,000,000 | - | - | - |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Parexel is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
